Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM8A120)

• Drug Name: RO7121661 Drug Info
• Synonyms: RG7769

Indication

Disease Entry	ICD 11	Status	REF
Esophageal squamous cell carcinoma	2E60.1	Phase 2	[1]

• Cross-matching ID: TTD Drug ID: DM8A120

Molecule-Related Drug Atlas

Drug(s) Targeting Programmed cell death protein 1 (PD-1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nivolumab	DMAB9QE	Melanoma	2C30	Approved	[3]
Tislelizumab	DMGVUO5	Hodgkin lymphoma	2B30	Approved	[4]
MK-3475	DMBYNW0	Melanoma	2C30	Approved	[3]
Pembrolizumab	DMFQEA6	Melanoma	2C30	Approved	[5]
Cemiplimab	DMKMJHE	Cutaneous squamous cell carcinoma	2C30	Approved	[6]
Retifanlimab	DMRKTCP	Neuroendocrine cancer	2B72.1	Approved	[7]
Sintilimab	DMGWR0C	Hodgkin lymphoma	2B30	Approved	[8]
Dostarlimab	DM78NWP	Endometrial cancer	2C76	Approved	[9]
Toripalimab	DMSGA6Z	Demodex blepharitis	1G07	Approved in China	[10]
PDR001	DM53J6B	Melanoma	2C30	Phase 3	[11]

Drug(s) Targeting Hepatitis A virus cellular receptor 2 (TIM3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
MBG453	DMBPY9Z	Myelodysplastic syndrome	2A37	Phase 3	[12]
GSK4069889	DMV6SNU	Non-small-cell lung cancer	2C25	Phase 2	[13]
AZD7789	DMOIHWI	Hodgkin lymphoma	2B30	Phase 2	[14]
TB006	DMKN524	Alzheimer disease	8A20	Phase 2	[15]
BGB-A425	DMI42Q0	Non-small-cell lung cancer	2C25	Phase 1/2	[16]
LY3415244	DM5QO1A	Solid tumour/cancer	2A00-2F9Z	Phase 1	[17]
LY3321367	DMD51GC	Solid tumour/cancer	2A00-2F9Z	Phase 1	[12]
Sym023	DMV3L62	Lymphoma	2A80-2A86	Phase 1	[18]
INCAGN2390	DM5SO1T	Solid tumour/cancer	2A00-2F9Z	Phase 1	[19]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Hepatitis A virus cellular receptor 2 (TIM3)	TT1RWL7	HAVR2_HUMAN	Inhibitor	[2]
Programmed cell death protein 1 (PD-1)	TTNBFWK	PDCD1_HUMAN	Inhibitor	[2]

References

• [1] ClinicalTrials.gov (NCT04785820) A Study of RO7121661 and RO7247669 Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus. U.S. National Institutes of Health.
• [2] Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019 Aug;18(8):585-608.
• [3] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [4] Tislelizumab: an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC). Expert Opin Investig Drugs. 2020 Dec;29(12):1355-1364.
• [5] Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730.
• [6] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [7] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [8] Sintilimab: First Global Approval. Drugs. 2019 Feb;79(3):341-346.
• [9] Dostarlimab in the treatment of recurrent or primary advanced endometrial cancer. Future Oncol. 2021 Mar;17(8):877-892.
• [10] Toripalimab: the First Domestic Anti-Tumor PD-1 Antibody in China. Front Immunol. 2022 Jan 12;12:730666.
• [11] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [12] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [13] Clinical pipeline report, company report or official report of GlaxoSmithKline.
• [14] Clinical pipeline report, company report or official report of AstraZeneca
• [15] Clinical pipeline report, company report or official report of TrueBinding
• [16] Clinical pipeline report, company report or official report of BeiGene.
• [17] Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors. Clin Cancer Res. 2021 May 15;27(10):2773-2781.
• [18] Clinical pipeline report, company report or official report of Symphogen.
• [19] Clinical pipeline report, company report or official report of Agenus.